Global gene expression in neuroendocrine tumors from patients with the MEN1 syndrome

Molecular Cancer

Volumn 4, Issue , 2005, Pages

  Dilley, William G ^a   Kalyanaraman, Somasundaram ^a   Verma, Sulekha ^b   Cobb, J Perren ^a   Laramie, Jason M ^a   Lairmore, Terry C ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLIN; FIBROBLAST GROWTH FACTOR 9; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHIONINE; NUCLEOSIDE DIPHOSPHATE KINASE A; SMAD3 PROTEIN; TRANSCRIPTION FACTOR AP 1; TUMOR SUPPRESSOR PROTEIN; HORMONE;

ADULT; APOPTOSIS; AUTOSOMAL DOMINANT DISORDER; BRAIN CANCER; CANCER PATIENT; CARCINOGENESIS; CELL DEATH; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONSENSUS SEQUENCE; CONTROLLED STUDY; CORRELATION COEFFICIENT; ENDOMETRIUM CANCER; FEMALE; GENE EXPRESSION; GENE NUMBER; GENE REPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CODE; GENETIC IDENTIFICATION; GENETIC SELECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOPHYSIS TUMOR; IN VITRO STUDY; MALE; MULTIPLE ENDOCRINE NEOPLASIA; NEUROENDOCRINE TUMOR; NUCLEOTIDE SEQUENCE; PANCREAS ISLET CELL; PANCREAS ISLET CELL TUMOR; PARATHYROID TUMOR; PROSTATE CANCER; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN MOTIF; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION; TUMOR GROWTH; UNINDEXED SEQUENCE; ARTICLE; CASE CONTROL STUDY; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; REPRODUCIBILITY; SYNDROME;

ADULT; CASE-CONTROL STUDIES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HORMONES; HUMANS; MALE; MIDDLE AGED; MULTIPLE ENDOCRINE NEOPLASIA TYPE 1; NEUROENDOCRINE TUMORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SYNDROME;

EID: 13644254118     PISSN: 14764598     EISSN: None     Source Type: Journal    
DOI: 10.1186/1476-4598-4-9     Document Type: Review

References (71)

1. Wermer P: Genetic aspects of adenomatosis of the endocrine glands. Am J Med 1954, 16:363-371.
2. Marx SJ, Agarwal SK, Kester MB, Heppner C, Kim YS, Skarulis MC, James LA, Goldsmith PK, Saggar SK, Park SY, et al: Multiple endocrine neoplasia type 1: clinical and genetic features of the hereditary endocrine neoplasias. Recent Prog Horm Res 1999, 54:397-438; discussion 438-399.
3. Knudsen AJ: Mutation and Cancer. Proc Natl Acad Sci U S A 1971, 68:820-823.
4. Chandrasekharappa SC, Guru SC, Manickam P, Olufemi SE, Collins FS, Emmert-Buck MR, Debelenko LV, Zhuang Z, Lubensky IA, Liotta LA, et al: Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276:404-407.
5. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, Spiegel AM, Marx SJ: Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol Metab 2001, 12: 73-178.
6. Mutch MG, Dilley WG, Sanjurjo F, DeBenedetti MK, Doherty GM, Wells SA, Jr., Goodfellow PJ, Lairmore TC: Germline mutations in the multiple endocrine neoplasia type 1 gene: evidence for frequent splicing defects. Hum Mutat 1999, 13:175-185.
7. Guru SC, Goldsmith PK, Burns AL, Marx SJ, Spiegel AM, Collins FS, Chandrasekharappa SC: Menin, the product of the MEN1 gene, is a nuclear protein. Proc Natl Acad Sci U S A 1998, 95: 630-1634.
8. Agarwal SK, Guru SC, Heppner C, Erdos MR, Collins RM, Park SY, Saggar S, Chandrasekharappa SC, Collins FS, Spiegel AM, et al: Menin interacts with the AP1 transcription factor JunD and represses JunD-activated transcription. Cell 1999, 96:143-152.
9. Gobl AE, Berg M, Lopez-Egido JR, Oberg K, Skogseid B, Westin G: Menin represses JunD-activated transcription by a histone deacetylase-dependent mechanism. Biochim Biophys Acta. 1999, 1447:51-56.
10. Agarwal SK, Novotny EA, Crabtree JS, Weitzman JB, Yaniv M, Burns AL, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ: Transcription factor JunD, deprived of menin, switches from growth suppressor to growth promoter. Proc Natl Acad Sci U S A 2003, 100:10770-10775.
11. Thepot D, Weitzman JB, Barra J, Segretain D, Stinnakre MG, Babinet C, Yaniv M: Targeted disruption of the murine junD gene results in multiple defects in male reproductive function. Development 2000, 127:143-153.
12. Stewart C, Parente F, Piehl F, Farnebo F, Quincey D, Silins G, Bergman L, Carle GF, Lemmens I, Grimmond S, et al: Characterization of the mouse Men1 gene and its expression during development. Oncogene 1998, 17:2485-2493.
13. Lemmens IH, Forsberg L, Pannett AA, Meyen E, Piehl F, Turner JJ, Van de Ven WJ, Thakker RV, Larsson C, Kas K: Menin interacts directly with the homeobox-containing protein Pem. Biochem Biophys Res Commun 2001, 286:426-431.
14. Brandi ML, Weber G, Svensson A, Falchetti A, Tonelli F, Castello R, Furlani L, Scappaticci S, Fraccaro M, Larsson C: Homozygotes for the autosomal dominant neoplasia syndrome (MEN1). Am J Hum Genet, 53:1167-1172.
15. Kaji H, Canaff L, Lebrun JJ, Goltzman D, Hendy GN: Inactivation of menin, a Smad3-interacting protein, blocks transforming growth factor type beta signaling. Proc Natl Acad Sci U S A 2001, 98:3837-3842.
16. Heppner C, Bilimoria KY, Agarwal SK, Kester M, Whitty LJ, Guru SC, Chandrasekharappa SC, Collins FS, Spiegel AM, Marx SJ, Burns AL: The tumor suppressor protein menin interacts with NF-kappaB proteins and inhibits NF-kappaB-mediated transactivation. Oncogene2001, 20:4917-4925.
17. Ohkura N, Kishi M, Tsukada T, Yamaguchi K: Menin, a gene product responsible for multiple endocrine neoplasia type 1, interacts with the putative tumor metastasis suppressor nm23. Biochem Biophys Res Commun 2001, 282:1206-1210.
18. Liberati NT, Datto MB, Frederick JP, Shen X, Wong C, Rougier-Chapman EM, Wang XF: Smads bind directly to the Jun family of AP-1 transcription factors. Proc Natl Acad Sci U S A 1999, 96:4844-4849.
19. Lopez-Rovira T, Chalaux E, Rosa JL, Bartrons R, Ventura F: Interaction and functional cooperation of NF-kappa B with Smads. Transcriptional regulation of the junB promoter. J Biol Chem 2000, 275:28937-28946.
20. Bitzer M, von Gersdorff G, Liang D, Dominguez-Rosales A, Beg AA, Rojkind M, Bottinger EP: A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappa B/RelA. Genes Dev 2000, 14: 87-197.
21. Rahmani M, Peron P, Weitzman J, Bakiri L, Lardeux B, Bernuau D: Functional cooperation between JunD and NF-kappaB in rat hepatocytes. Oncogene 2001, 20:5132-5142.
22. Alon U, Barkai N, Notterman DA, Gish K, Ybarra S, Mack D, Levine AJ: Broad patterns of gene expression revealed by clustering analysis of tumor and normal colon tissues probed by oligonucleotide arrays. Proc Natl Acad Sci U S A 1999, 96:6745-6750.
23. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, Downing JR, Caligiuri MA, et al: Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999, 286:531-537.
24. Alizadeh AA, Ross DT, Perou CM, van de Rijn M: Towards a novel classification of human malignancies based on gene expression patterns. J Pathol 2001, 195:41-52.
25. Su AI, Welsh JB, Sapinoso LM, Kern SG, Dimitrov P, Lapp H, Schultz PG, Powell SM, Moskaluk CA, Frierson HF, Jr., Hampton GM: Molecular classification of human carcinomas by use of gene expression signatures. Cancer Res 2001, 61:7388-7393.
26. Ramaswamy S, Tamayo P, Rifkin R, Mukherjee S, Yeang CH, Angelo M, Ladd C, Reich M, Latulippe E, Mesirov JP, et al: Multiclass cancer diagnosis using tumor gene expression signatures. Proc Natl Acad Sci U S A 2001, 98:15149-15154.
27. Wu TD: Analysing gene expression data from DNA microarrays to identify candidate genes. J Pathol 2001, 195:53-65.
28. Harkin DP: Uncovering functionally relevant signaling pathways using microarray-based expression profiling. Oncologist 2000, 5:501-507.
29. Li C, Hung Wong W: Model-based analysis of oligonucleotide arrays: model validation, design issues and standard error application. Genome Biol 2001, 2:RESEARCH0032.
30. Li C, Wong WH: Model-based analysis of oligonucleotide arrays: expression index computation and outlier detection. Proc Natl Acad Sci U S A 2001, 98:31-36.
31. Komminoth P, Heitz PU, Kloppel G: Pathology of MEN-1: morphology, clinicopathologic correlations and tumour development. J Intern Med 1998, 243:455-464.
32. Cardozo AK, Heimberg H, Heremans Y, Leeman R, Kutlu B, Kruhoffer M, Orntoft T, Eizirik DL: A comprehensive analysis of cytokine-induced and nuclear factor-kappa B-dependent genes in primary rat pancreatic betacells. J Biol Chem 2001, 276: 8879-48886.
33. Shalev A, Pise-Masison CA, Radonovich M, Hoffmann SC, Hirshberg B, Brady JN, Harlan DM: Oligonucleotide microarray analysis of intact human pancreatic islets: identification of glucose-responsive genes and a highly regulated TGFbeta signaling pathway. Endocrinology 2002, 143:3695-3698.
34. Scearce LM, Brestelli JE, McWeeney SK, Lee CS, Mazzarelli J, Pinney DF, Pizarro A, Stoeckert CJ, Jr., Clifton SW, Permutt MA, et al: Functional genomics of the endocrine pancreas: the pancreas clone set and PancChip, new resources for diabetes research. Diabetes 2002, 51:1997-2004.
35. Maitra A, Hansel DE, Argani P, Ashfaq R, Rahman A, Naji A, Deng S, Geradts J, Hawthorne L, House MG, Yeo CJ: Global expression analysis of well-differentiated pancreatic endocrine neoplasms using oligonucleotide microarrays. Clin Cancer Res 2003, 9: 988-5995.
36. Schnepp RW, Mao H, Sykes SM, Zong WX, Silva A, La P, Hua X: Menin induces apoptosis in murine embryonic fibroblasts. J Biol Chem 2004, 279:10685-10691.
37. Wu MX: Roles of the stress-induced gene IEX-1 in regulation of cell death and oncogenesis. Apoptosis 2003, 8: 1-18.
38. Arlt A, Grobe O, Sieke A, Kruse ML, Folsch UR, Schmidt WE, Schafer H: Expression of the NF-kappa B target gene IEX-1 (p22/PRG1) does not prevent cell death but instead triggers apoptosis in Hela cells. Oncogene 2001, 20:69-76.
39. Schilling D, Pittelkow MR, Kumar R: IEX-1, an immediate early gene, increases the rate of apoptosis in keratinocytes. Oncogene 2001, 20:7992-7997.
40. Osawa Y, Nagaki M, Banno Y, Brenner DA, Nozawa Y, Moriwaki H, Nakashima S: Expression of the NF-kappa B target gene X-ray-inducible immediate early response factor-1 short enhances TNF-alpha-induced hepatocyte apoptosis by inhibiting Akt activation. J Immunol 2003, 170:4053-4060.
41. Albini A, Florio T, Giunciuglio D, Masiello L, Carlone S, Corsaro A, Thellung S, Cai T, Noonan DM, Schettini G: Somatostatin controls Kaposi's sarcoma tumor growth through inhibition of angiogenesis. FASEB J 1999, 13:647-655.
42. Arnold R, Wied M, Behr TH: Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract. Expert Opin Pharmacother 2002, 3:643-656.
43. Benali N, Cordelier P, Calise D, Pages P, Rochaix P, Nagy A, Esteve JP, Pour PM, Schally AV, Vaysse N, et al: Inhibition of growth and metastatic progression of pancreatic carcinoma in hamster after somatostatin receptor subtype 2 (sst2) gene expression and administration of cytotoxic somatostatin analog AN-238. Proc Natl Acad Sci U S A 2000, 97:9180-9185.
44. Borgstrom P, Hassan M, Wassberg E, Refai E, Jonsson C, Larsson SA, Jacobsson H, Kogner P: The somatostatin analogue octreotide inhibits neuroblastoma growth in vivo. Pediatr Res 1999, 46:328-332.
45. Chatzistamou I, Schally AV, Varga JL, Groot K, Armatis P, Busto R, Halmos G: Antagonists of growth hormone-releasing hormone and somatostatin analog RC-160 inhibit the growth of the OV-1063 human epithelial ovarian cancer cell line xenografted into nude mice. J Clin Endocrinol Metab 2001, 86:2144-2152.
46. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, Albini A: Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144:1574-1584.
47. Georgii-Hemming P, Stromberg T, Janson ET, Stridsberg M, Wiklund HJ, Nilsson K: The somatostatin analog octreotide inhibits growth of interleukin-6 (IL-6)-dependent and IL-6-independent human multiple myeloma cell lines. Blood 1999, 93:1724-1731.
48. Hoelting T, Duh QY, Clark OH, Herfarth C: Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo. J Clin Endocrinol Metab 1996, 81:2638-2641.
49. Ishihara S, Hassan S, Kinoshita Y, Moriyama N, Fukuda R, Maekawa T, Okada A, Chiba T: Growth inhibitory effects of somatostatin on human leukemia cell lines mediated by somatostatin receptor subtype 1. Peptides 1999, 20:313-318.
50. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P: Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II. Cancer 1998, 82:909-917.
51. Kahan Z, Nagy A, Schally AV, Hebert F, Sun B, Groot K, Halmos G: Inhibition of growth of MX-1, MCF-7-MIII and MDA-MB-231 human breast cancer xenografts after administration of a targeted cytotoxic analog of somatostatin, AN-238. Int J Cancer 1999, 82: 92-598.
52. Kiaris H, Schally AV, Nagy A, Szepeshazi K, Hebert F, Halmos G: A targeted cytotoxic somatostatin (SST) analogue, AN-238, inhibits the growth of H-69 small-cell lung carcinoma (SCLC) and H-157 non-SCLC in nude mice. Eur J Cancer 2001, 37:620-628.
53. Kikutsuji T, Harada M, Tashiro S, Ii S, Moritani M, Yamaoka T, Itakura M: Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers. J Hepatobiliary Pancreat Surg 2000, 7:496-503.
54. Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, de Jong M, Jamar F, Pauwels S: The role of radioactive somatostatin and its analogues in the control of tumor growth. Recent Results Cancer Res 2000, 153:1-13.
55. Mishima M, Yano T, Jimbo H, Yano N, Morita Y, Yoshikawa H, Schally AV, Taketani Y: Inhibition of human endometrial cancer cell growth in vitro and in vivo by somatostatin analog RC-160. Am J Obstet Gynecol 1999, 181:583-590.
56. Pinski J, Schally AV, Halmos G, Szepeshazi K, Groot K: Somatostatin analog RC-160 inhibits the growth of human osteosarcomas in nude mice. Int J Cancer 1996, 65:870-874.
57. Zatelli MC, Tagliati F, Piccin D, Taylor JE, Culler MD, Bondanelli M, degli Uberti EC: Somatostatin receptor subtype 1-selective activation reduces cell growth and calcitonin secretion in a human medullary thyroid carcinoma cell line. Biochem Biophys Res Commun 2002, 297:828-834.
58. Lee MP, Feinberg AP: Genomic imprinting of a human apoptosis gene homologue, TSSC3. Cancer Res 1998, 58: 052-1056.
59. Muller S, van den Boom D, Zirkel D, Koster H, Berthold F, Schwab M, Westphal M, Zumkeller W: Retention of imprinting of the human apoptosis-related gene TSSC3 in human brain tumors. Hum Mol Genet 2000, 9: 757-763.
60. Gebre-Medhin S, Olofsson C, Mulder H: Islet amyloid polypeptide in the islets of Langerhans: friend or foe? Diabetologia 2000, 43:687-695.
61. Itoh H, Takei K: Immunohistochemical and statistical studies on the islets of Langerhans pancreas in autopsied patients after gastrectomy. Hum Pathol 2000, 31:1368-1376.
62. Karlsson E, Sandler S: Islet amyloid polypeptide promotes beta-cell proliferation in neonatal rat pancreatic islets . Diabetologia 2001, 44:1015-1018.
63. Rumora L, Hadzija M, Barisic K, Maysinger D, Grubiic TZ: Amylin-induced cytotoxicity is associated with activation of caspase-3 and MAP kinases. Biol Chem 2002, 383:1751-1758.
64. Zhang S, Liu J, MacGibbon G, Dragunow M, Cooper GJ: Increased expression and activation of c-Jun contributes to human amylin-induced apoptosis in pancreatic islet beta-cells. J Mol Biol 2002, 324:271-285.
65. Miyagi N, Kato S, Terasaki M, Aoki T, Sugita Y, Yamaguchi M, Shigemori M, Morimatsu M: Fibroblast growth factor-9 (glia-activating factor) stimulates proliferation and production of glial fibrillary acidic protein in human gliomas either in the presence or in the absence of the endogenous growth factor expression. Poncol Rep 1999,6 87-92.
66. Weksler NB, Lunstrum GP, Reid ES, Horton WA: Differential effects of fibroblast growth factor (FGF) 9 and FGF2 on proliferation, differeniation and terminal differentiation of chondrocytic cells in vitro. Biochem J 1999, 342:677-682.
67. Giri D, Ropiquet F, Ittmann M: FGF9 is an autocrine and paracrine prostatic growth factor expressed by prostatic stromal cells. J Cell Physiol 1999, 180:53-60.
68. Tsai SJ, Wu MH, Chen HM, Chuang PC, Wing LY: Fibroblast growth factor-9 is an endometrial stromal growth factor. Endocrinology 2002, 143:2715-2721.
69. Matsumoto-Yoshitomi S, Habashita J, Nomura C, Kuroshima K, Kurokawa T: Autocrine transformation by fibroblast growth factor 9 (FGF-9) and its possible participation in human oncogenesis. Int J Cancer 1997, 71:442-450.
70. Busygina V, Suphapeetiporn K, Marek LR, Stowers RS, Xu T, Bale AE: Hypermutability in a Drosophila model for multiple endocrine neoplasia type 1. Hum Mol Genet 2004, 13:2399-2408.
71. Olack BJ, Swanson CJ, Howard TK, Mohanakumar T: Improved method for the isolation and purification of human islets of langerhans using Liberase enzyme blend. Hum Immunol 1999, 60: 303-1309.